BRIEF-ProMIS Neurosciences lead product candidate, PMN310, shows desired target binding profile

1 Min Read

Oct 17 (Reuters) - ProMIS Neurosciences Inc

* ProMIS Neurosciences lead product candidate, PMN310, shows desired target binding profile in direct comparison to other amyloid beta-directed antibodies for alzheimer’s disease Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below